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Two well defined mutations, including the NPM1 and 
CCAAT/enhancer-binding protein-alpha (CEBPA) genes, 
are generally accepted as a better prognosis in AML [1]. 
NPM1, one of frequent mutations in AML, have been de-
scribed in association with several clinical features, includ-
ing a normal karyotype and a significantly higher long-term 
survival benefit compared to those patients who are having 
other mutations. However, there have been many reports, 
although they are not confirmative yet, about the role of 
this specific mutation whether it is really positive or negative 
influential to the response after chemotherapy and/or hema-
topoietic stem cell transplantation (HSCT). Is the mutational 
state of NPM1 alone or in combination with other defined 
mutations in AML matter when we treat the patients in 
any manner, i.e. either use of conventional chemothera-
peutic agents or novel developmental agents introduced re-
cently or even combination of sequential chemotherapies 
followed by HSCT? There is no clear answer yet un-
fortunately. 
Furthermore, some studies showed that although NPM1 
mutation was a favorable factor for achieving complete re-
mission (CR), it was even associated with a higher relapse 
rate and poorer disease-free survival (DFS) [2]. What is 
more interesting, the mutational state of NPM1 alone had 
no significant effect on DFS and could not be a favorable 
prognostic factor for AML [3, 4]. Finally, no clinical sig-
nificance for this mutation with respect to overall survival 
(OS) was described in any of these reports. Also, there is 
another recent Korean report that non-A subtype NPM1 
mutation predicts poor clinical outcome in de novo adult 
AML [5].
Because of the large variability of gene mutations or the 
heterogeneity of AML, it is basically understood as a very 
complex disease entity having diverse prognosticators. 
Therefore, many combinations of molecular markers in asso-
ciation with treatment outcome of AML have been in-
troduced recently. Although there is not enough evidence 
to insist of positive impact on clinical outcome of NPM1 
mutation, it seems like that patients with isolated NPM1 
mutation (NPM1mut) generally had a better outcome in 
terms of either OS or DFS as compared to the group of 
NPM1mut+/FLT3 -ITD+ patients [6, 7]. In contrast, most 
studies have reported that FLT3 -ITD+ is an independent 
poor prognostic factor contributing to an increased risk of 
induction failure and finally poor survival.
Based on these concepts, Kim et al. [8] showed in previous 
issue of the Korean Journal of Hematology that adult patient 
with cytogenetically normal-AML (CN-AML) carrying iso-
lated NPM1mut who performed allogeneic HSCT resulted 
in much higher 5-year relapse-free survival rate than those 
treated with high-dose cytarabine (HDAC) chemotherapy 
only as intensified consolidation therapy. Their results have 
profound meaning, but some critical limitations exist. This 
single institutional data of 121 adult CN-AML patients re-
ceived the standard ‘3×7’ induction chemotherapy using 
idarubicin plus cytosine arabinoside or BH-AC and then 
received 1-3 courses of HDAC consolidation chemotherapy 
(in total of 18 g/m
2 cytosine arabinoside per cycle). Among 
the patients carrying isolated NPM1mut, only 13 out of 
35 patients received allogeneic HSCT with an extremely 
short median follow-up duration of 11.8 months. Most of 
all, all patients enrolled in this cohort showed the type Korean J Hematol 2010;45:79-80.
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A mutation. Specifically, other subtype mutation of NPM1 
would be researchable in them. Like other studies published 
recently, they did not comprise any other complex set of 
mutations such as ERG, BAALC, c-kit, Ras, WT1, PRAME, 
MN1 etc [9]. Those numerous considerable parameters when 
treat AML would be also feasible if we can focus on the 
importance of molecular biogenetic characteristics of AML. 
Although this study is truly suggestive as a 1
st comparison 
analysis in Korean NPM1mut CN-AML, it should be cautious 
not to consider any definite role of allogeneic HSCT for 
the subgroup of patients at the moment. This retrospective 
study is worth to reviewing with intermediate sample num-
bers of adult Korean AML in a single institution. However, 
it is not acceptable to take allogeneic HSCT for this subgroup 
of specific patient population, i.e. isolated NPM1mut CN- 
AML. Concerning FLT3 -ITD mutation (FLT3 -ITD+) in pa-
tients with CN-AML, isolated FLT3 -ITD+ showed poor sur-
vivals, similar to those with poor-risk cytogenetics as shown 
in other previous reports [4, 10]. We need our own study 
to verify these foreign data performed absolutely with 
Caucasian. Most of all, we need a pharmacogenomic data 
for Korean by using various present (including HDAC strat-
egy established by most Caucasian data) and/or future an-
ti-leukemic agents. We then set the best therapeutic strategy 
for Korean AML based on those population genetics as well 
as our own clinical experiences.
There has been no study revealed the issue of appropriate 
treatment of NPM1mut-CN-AML with HDAC vs. HSCT. 
Although the NCCN guidelines for AML consider patients 
with isolated NPM1mut as a usual favorable-risk group, 
like in core-binding factor subgroup of AML, we should 
have definite answer for this interesting question in near 
future. As authors suggested, post-remission treatment for 
isolated NPM1mut could be investigated in a randomized 
study of allogeneic HSCT vs. repeated courses of HDAC 
vs. autologous HSCT. Further, more diligent work for find-
ing other subtypes of NPM1/FLT3 -ITD mutants together 
with more novel combinatorial molecular markers regarding 
expression of multiple genes in leukemogenesis will have 
a great impact on understanding of AML. The report by 
Kim et al. [8] should be a meaningful first step forward 
to enlighten these tough tasks we confront so far, and there-
fore more data in the context of more sample numbers 
with more fine analyses are further needed to shed light 
onto a basis of novel target therapy in AML. Let’s get ready 
to use more arms!
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